Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01126450 · ClinicalTrials.gov registry record · Phase 1
Lenalidomide and Cetuximab in Treating Patients With Metastatic Colorectal Cancer
A Phase 1 study, sponsored by Case Comprehensive Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT01126450 is a Phase 1 study that was terminated before completion, run by Case Comprehensive Cancer Center. The registered enrollment target is 3 participants.
The verdict
NCT01126450, a Phase 1 study, was terminated before completion, sponsored by Case Comprehensive Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
RATIONALE: Lenalidomide may stop the growth of tumor cells by blocking blood flow to the tumor. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving lenalidomide together with cetuximab may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of lenalidomide when given together with cetuximab in treating patients with metastatic colorectal cancer.
Interventions
- DRUG lenalidomide
- BIOLOGICAL cetuximab
- GENETIC polymorphism analysis
- OTHER polymerase chain reaction
- OTHER mutation analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2009-10 |
| Est. Completion | 2010-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01126450
The ClinicalTrials.gov registry entry for NCT01126450 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which lenalidomide is the first listed.
NCT01126450 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01126450 about?
NCT01126450 is a clinical study titled "Lenalidomide and Cetuximab in Treating Patients With Metastatic Colorectal Cancer". RATIONALE: Lenalidomide may stop the growth of tumor cells by blocking blood flow to the tumor. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-kill...
What is the current status of trial NCT01126450?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2009-10. Estimated completion is 2010-12.
What interventions are being tested in trial NCT01126450?
The interventions under investigation include: lenalidomide (DRUG), cetuximab (BIOLOGICAL), polymorphism analysis (GENETIC), polymerase chain reaction (OTHER), mutation analysis (OTHER).
Who is sponsoring clinical trial NCT01126450?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.